Cargando…
The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
SIMPLE SUMMARY: ANCA-associated vasculitis (AAV) is a rare disease and manifests in different organs. The exact mechanism of AAV is not fully understood, but it is speculated that it is induced by autoantibody production against proteinase-3 and myeloperoxidase. Patients diagnosed with ANCA-associat...
Autores principales: | Habibi, Mohammad Amin, Alesaeidi, Samira, Zahedi, Mohadeseh, Hakimi Rahmani, Samin, Piri, Seyed Mohammad, Tavakolpour, Soheil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774915/ https://www.ncbi.nlm.nih.gov/pubmed/36552276 http://dx.doi.org/10.3390/biology11121767 |
Ejemplares similares
-
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020) -
PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013) -
Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017) -
Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020) -
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)